1. The Efficacy and Safety of a Qiliqiangxin Capsule Combined with Sacubitril/Valsartan in the Treatment of Chronic Heart Failure: A Systematic Review and Meta‐Analysis
   Wensheng Chen et al, 2023, Evidence-Based Complementary and Alternative Medicine CrossRef
2. Recent pharmacological advances in the treatment of cardiovascular events with Astragaloside IV
   Zehui Xu et al, 2023, Biomedicine & Pharmacotherapy CrossRef
3. SUMO: A new perspective to decipher fibrosis
   Ling Li et al, 2024, Acta Physiologica CrossRef
4. Effect of Astragaloside IV on improving cardiac function in rats with heart failure: a preclinical systematic review and meta-analysis
   Zhiyuan Zhang et al, 2023, Frontiers in Pharmacology CrossRef
5. Traditional Chinese Medicine Monomers Are Potential Candidate Drugs for Cancer-Induced Cardiac Cachexia
   Zhizheng Li et al, 2024, Pharmacology CrossRef
6. The state of astragaloside IV research: A bibliometric and visualized analysis
   Ning Liu et al, 2024, Fundamental & Clinical Pharmacology CrossRef
7. Cardioprotective Effects and Mechanisms of Saponins on Cardiovascular Disease
   Xin Ma et al, 2022, Natural Product Communications CrossRef
8. SUMO-specific protease 1 inhibitors–A literature and patent overview
   Hang Li et al, 2022, Expert Opinion on Therapeutic Patents CrossRef
9. Natural Products Against Renal Fibrosis via Modulation of SUMOylation
   Peng Liu et al, 2022, Frontiers in Pharmacology CrossRef
10. The traditional Chinese medicines treat chronic heart failure and their main bioactive constituents and mechanisms
    Jie Chen et al, 2023, Acta Pharmaceutica Sinica B CrossRef
11. Natural products from traditional Chinese medicine for the prevention and treatment of heart failure: progress and perspectives
    Linhao Xu et al, 2022, Reviews in Cardiovascular Medicine CrossRef
12. Astragaloside IV for Heart Failure: Preclinical Evidence and Possible Mechanisms, A Systematic Review and Meta-Analysis
    Xing-xing Li et al, 2023, Chinese Journal of Integrative Medicine CrossRef